Who is it for?

how to use it?

Apply a few drops to the face after cleansing, before using emulsions and/or creams. Can be used either in the AM and/or PM.
Shelf life: 2 years from production (unopened), 6 months PAO (period after opening)

Ingredients & Research

key ingredients:

Potassium Azeloyl Diglycinate –  A new generation azelaic acid derivative designed to be water-soluble and thus enable light formulas. It has a similar effect to the 3-in-1 clinical active azelaic acid that helps to reduce blemishes, pigmentation, and redness. The two strong point of PAD is to even the skin tone and to control excessive oiliness.  aPAD contains 20% Azeclair, the trade name of the PAD solution we are using in the product. This means 6% of pure Potassium Azeloyl Diglycinate. (Note: the formula has not changed, but we have corrected the communication mistake we made with aPAD. We really apalogize, and have written in detail about what happened here. ) 

Allantoin -A classic skincare ingredient known for its skin soothing and skin protecting abilities.

Glycerin & Methyl-Gluceth 20: A gentle humectant combination to help the skin to hold onto water.

full inci list:

Water, Potassium Azeloyl Diglycinate, Propanediol, Glycerin, Methyl-Gluceth 20, Allantoin, Hydroxyethylcellulose, Xanthan Gum, Citric Acid, Ethylhexylglycerin, Phenoxyethanol

research:

Berardesca, Enzo, et al. "Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea." Journal of cosmetic dermatology 11.1 (2012): 37-41.

Viyoch, Jarupa, et al. "Effects of trans-4-(aminomethyl) cyclohexanecarboxylic acid/potassium azeloyl diglycinate/niacinamide topical emulsion in Thai adults with melasma: a single-center, randomized, double-blind, controlled study." Current Therapeutic Research 71.6 (2010): 345-359.

Veraldi, Stefano, et al. "Treatment of symptoms of erythemato-telangiectatic rosacea with topical potassium azeloyl diglycinate and hydroxypropyl chitosan: Results of a sponsor-free, multicenter, open study." Journal of Dermatological Treatment 26.2 (2015): 191-192.